Using organic acids to diagnose and manage recalcitrant patients

Alternative Therapies in Health and Medicine

Volumn 12, Issue 4, 2006, Pages 44-51

  Rogers, Sherry A ^a,b,c  

^a Asthma and Immunology   (United States)

^b American College of Nutrition   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BIOCHEMICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYLIC ACID; CARNITINE; FATTY ACID; FOLIC ACID; GLYCINE; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PANTOTHENIC ACID; PYRIDOXINE; SEX HORMONE; THIAMINE; THIOCTIC ACID; TOCOPHEROL; TOXIN; UBIDECARENONE; VITAMIN;

AGING; BLOOD LEVEL; BRAIN ATROPHY; CANCER; CLINICAL TRIAL; DETOXIFICATION; DIABETES MELLITUS; DIET; ENVIRONMENTAL FACTOR; EPIDEMIC; FOLIC ACID DEFICIENCY; HUMAN; INSULIN RESISTANCE; INTELLECTUAL IMPAIRMENT; INTESTINE FLORA; LABORATORY TEST; METABOLISM; MINERAL DEFICIENCY; NUTRIENT; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; VITAMIN DEFICIENCY;

AVITAMINOSIS; DEFICIENCY DISEASES; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; HAZARDOUS SUBSTANCES; HOMOCYSTEINE; HUMANS; MALNUTRITION; METHIONINE; NEOPLASMS; NUTRITION DISORDERS;

EID: 33746394999     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Perera FP. Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention, J Natl Cancer Inst. 1996;88(8):496-509, Apr. 17, 1996
2. Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population [see comments]. Am J Clin Nutr. 1994;60(1):2-11.
3. Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methyl malonic acid, and total homocysteine concentrations, Am J Haematol. 1990;34(2):99-107.
4. Jernal M. High-throughput quantitative bioanalysis by LC/MS/MS. Biomed Chromatogr. 2000;14(6):422-429.
5. Anonymous. News & Views: Study sees benefit in high-dose chemotherapy for breast cancer. CA Cancer J Clin. 2006;56:63-64.
6. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338(12):777-783.
7. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA. 1999;281(16):1505-1511.
8. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7(5):439-443.
9. Vieth R. Vitamin D nutrition and its potential health benefits for bone, cancer and other conditions. J Nutr Environ Med. 2001;11:275-291.
10. Holick MF. Vitamin D: Importance in the prevention of cancer, type I diabetes, heart disease and osteoporosis. Am J Clin Nutr. 2004;79(5):362-371.
11. Vasquez AG, Manso G, Cannell J. The clinical importance of vitamin D (cholecalciferol): a paradigm shift with implications for all healthcare providers. Altern Ther Health Med. 2004;10(5):28-36; [quiz]37,94.
12. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr. 2003;89(5):552-572.
13. Drewel BT, Giraud DW, Davy SR, Driskell JA. Less than adequate vitamin E status observed in a group of preschool boys and girls living in the United States. J Nutr Biochem. 2006;17(2):132-138.
14. Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impatient of endothelium-dependent brachial artery vasoactivity following a single high-fat meal, JAMA. 1997;278(20):1682-1686.
15. Dutta A, Dutta SK. Vitamin E and it role in prevention of atherosclerosis and carcinogenesis; a review, J Am Coll Nutr. 2003;22(4):258-268.
16. Palumbo G, Avanzini F, Alli C, et al. Effects of vitamin E on clinic and ambulatory blood pressure in treated hypertensive patients. Am J Hypertens. 2000;13(5 pt 1):564-567.
17. Skyrme Jones RA, O'Brien RC, Berry KL, Meredith IT. Vitamin E supplementation improves endothelial function in type 1 diabetes: a randomized placebo-controlled study, J Am Coll Cardiol. 2000;36(1):94-102.
18. Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review. JAMA. 2002;287(23):3116-3126.
19. Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention in adults: clinical applications. JAMA. 2002;287(23):3127-3129.
20. Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA. 1995;273(23):1849-1854.
21. Sahyoun NR, Jacques PF, Russell RM. Carotenoids, vitamins C and E, and mortality in an elderly population. Am J Epidemiol. 1996;144(5):501-511.
22. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr. 1996;64(2):190-196.
23. Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002;75(4):616-658.
24. Whang R, Ryder KW. Frequency of hypomagnesemia and hypermagnesemia. Requested vs routine. [see comments] JAMA. 1990;263(22):3063-3064.
25. Anonymous, New misgivings about magnesium, Science News. 1988;133(32):356.
26. Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J. 1984;108(1):188-193.
27. Heckbert SR, Longstreth WT Jr, Psaty BM, et al. The association of antihypertensive agents with MRI white matter findings and with Modified Mini-Mental State Examination in older adults. J Am Geriatr Soc. 1997;45(12):1423-1433.
28. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997;80(8):1438-1447.
29. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274(8):620-625.
30. Singh RB, Cameron EA. Relation of myocardial magnesium deficiency to sudden death in ischemic heart disease. Am Heart J. 1982;103(3):449-450.
31. Rogers SA. The High Blood Pressure Hoax. Sarasota, FL: Sand Key publishing; 2005.
32. Pelton R, La Valle JB, Hawkins EB. Drug-Induced Nutrient Depletion Handbook. Hudson, OH: Lexi-Comp; 1999.
33. Landrigan PJ, Sonawane B, Drollaer D. Early environmental origins of neurodegenerative disease in later life, Environ Health Perspect. 2005;113(9):1230-1233.
34. Environmental Working Group. Body burden: The pollution in newborns. Available at: http://www.ewg.org/reports/bodyburden2/execsumm.php. Accessed June 5, 2006.
35. Centers for Disease Control and Prevention. National Report on Human Exposure to Environmental Chemicals. Available at: http://www.cdc.gov/ exposurereport/. Accessed June 6, 2006.
36. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352(11):1138-1145.
37. Rogers SA. The mystery of Syndrome X is solved, Total Wellness newsletter. Available at: https://secure.dreamscape.com/prestigepublishing/ html_web_store/html_web_store.cgi?page=news.htm&cart_id=7674865.21729.
38. Sonne C, Dietz R, Born EW, et al. Is bone mineral composition disrupted by organochlorines in east Greenland polar hears (Ursus maritimus)? Environ Health Perspect. 2004;112(17):1711-1716.
39. Braathen M, Derocher AE, Wiig O, et al. Relationships between PCBs and thyroid hormones and retinol in female and male polar bears. Environ Health Perspect. 2004;112(8):826-833.
40. Skaare JU, Bernhoft A, Wiig O, et al. Relationships between plasma levels of organochlorines, retinol and thyroid hormones from polar bears (Ursus maritimus) at Svalbard. J Toxicol Environ Health A. 2001;62(4):227-241.
41. Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A. The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. Environ Health Perspect. 2006;114(1):106-112.
42. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA. 1994;91(23):11012-11016.
43. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA. 1993;90(6):2160-2164.
44. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998;273(49):32833-32841.
45. Rogers SA. Detoxify or Die. Sarasota, Fla: Sand Key Company, Incorporated; 2002.
46. Braly J, Holford P. The H-Factor Solution: Homocysteine, the Best Single Indicator of Whether You Are Likely to Live Long or Die Young. North Bergen, NJ: Basic Health Pub.; 2003:242.
47. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202.
48. Rogers SA. No More Heartburn: Stop the Pain in 30 Days-Naturally! The Safe, Effective Way to Prevent and Heal Chronic Gastrointestinal Disorders. New York: Kensington Books; 2000:258.
49. Shojania AM. Oral contraceptives: effect of folate and vitamin B12 metabolism. Can Med Assoc J. 1982;126(3):244-247.
50. Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol. 2000;36(3):758-765.
51. Loria CM, Ingram DD, Feldman JJ, Wright JD, Madans JH. Serum folate and cardiovascular disease mortality among US men and women. Arch Intern Med. 2000;160(21):3258-3262.
52. Shrubsole MJ, Jin F, Dai Q, et al. Dietary folate intake and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Res. 2001;61(19):7136-7141.
53. Roubenoff R, et al. Malnutrition among hospitalized patients: problem of physician awareness. Arch Intern Med. 1987;147(8):1462-1465.
54. Guilliams TG. Homocysteine - A risk factor for vascular diseases: Guidelines for the clinical practice. J Am Nutraceut Assoc. 2004;7(1):1-24.
55. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation. 2000;102(20):2479-2483.
56. Stanger O, Semmelrock HJ, Wonisch W, Bos U, Pabst E, Wascher TC. Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects. J Pharmacol Exp Ther. 2002;303(1):158-162.
57. Marcucci R, Zanazzi M, Bertoni E, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation. 2003;75(9):1551-1555.
58. Vermeulen EG, Stehouwer CD, Twisk JW. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet. 2000;355(9203):517-522.
59. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345(22):1593- 1600.
60. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA. 2002;288(8):973-979.
61. Sellers TA, Kushi LH, Cerhan JR, et al. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology. 2001;12(4):420-428.
62. Schwartz, R., M. Topley, and J.B. Russell. Effect of tricarballylic acid, a nonmetabolizable rumen fermentation product of trans-aconitic acid, on Mg, Ca and Zn utilization of rats. J Nutr. 1988;118(2):183-188.
63. Ileit KF, Tee LB, Reeves PT, Minchin RF. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther. 1990;46(1):67-93.
64. Chadwick RW, George SE, Claxton LD. Role of the gastrointestinal mucosa and microflora in the bioactivation of dietary and environmental mutagens or carcinogens. Drug Metab Rev. 1992;24;(4):425-492.
65. Christensson B, Sigmundsdottir G, Larsson L. D-arabinitol-a marker for invasive candidiasis. Med Mycol. 1999;37(6):391-396.
66. Wong B, Bernard EM, Gold JW, Fong D, Armstrong D. The arabinitol appearance rate in laboratory animals and humans: estimation from the arabinitol/creatine ratio and relevance to the diagnosis of candidiasis. J Infect Dis. 1982;146(3):353-359.
67. Tokunaga S, Ohkawa M, Takashima M, Hisazumi H. Clinical significance of measurement of serum D-arabinitol levels in candiduria patients. Urol Int. 1992;48(2):95-99.
68. Roboz J. Diagnosis and monitoring of disseminated candidiasis based on serum/urine D/L-arabinitol ratios. Chirality. 19946(2):51-57.
69. Vojdani A, Rahimian P, Kalhor H, Mordechai E. Immunological cross reactivity between Candida albicans and human tissue. J Clin Lab Immunol. 1996;48(1):1-15.
70. Rogers SA. The E.I. Syndrome: An Rx for Environmental Illness. Syracuse, NY: Prestige Publications; 1986
71. Temellini A, Mogavero S, Giulianotti PC, Pietrabissa A, Mosca F, Pacifici GM. Conjugation of benzole acid with glycine in human liver and kidney: a study on the interindividual variability. Xenobiotica. 1993;23(12):1427-1433.
72. Mayer PJ, Beeken WL. The role of urinary indican as a predictor of bacterial colonization in the human jejunum. Am J Dig Dis. 1975;20(11):1003- 1009.
73. Montgomery RD, Haeney MR, Ross IN, et al. The ageing gut: a study of intestinal absorption in relation to nutrition in the elderly. Q J Med 1978;47(186):197-224.
74. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989-2995.
75. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39(1):54-59.
76. Rogers SA. Total Wellness. Syracuse, New York: Prestige Publishing; 1999-2006.
77. Zempleni J, Trusty TA, Mock DM. Lipoic acid reduces the activities of biotin-dependent carboxylases in rat liver. J Nutr 1997;127(9):1776-1781.
78. Koutsikos D, Fourtounas C, Kapetanaki A, et al. Oral glucose tolerance test after high-dose i.v. brotin administration in normoglucemic hemodialysis patients. Ren Fail. 1996;18(1):131-137.
79. Reddi A, DeAngelis B, Frank O, Lasker N, Baker H. Biotin supplementation improves glucose and insulin tolerances in genetically diabetic KK mice. Life Sci. 1988;42(13):1323-1330.
80. Zhang H, Osada K, Maebashi M, Ito M, Komai M, Furukawa Y. A high biotin diet improves the impaired glucose tolerance of long-term spontaneously hyperglycemic rats with non-insulin-dependent diabetes mellitus. J Nutr Sci Vitaminol (Tokyo). 1996;42(6):517-526.
81. Koutsikos D, Agroyannis B, Tzanatos-Exarchou H. Biotin for diabetic peripheral neuropathy. Biomed Pharmacother. 1990;44(10):511-514.
82. Mock DM, Henrich CL, Carnell N, Mock NI. Indicators of marginal biotin deficiency and repletion in humans: validation of 3-hydroxyisovaleric acid excretion and a leucine challenge. Am J Clin Nutr. 2002;76(5):1061-1068.
83. Krause KH, Berlit P, Bonjour JP, Schmidt-Gayk H, Schellenberg B, Gillen J. Vitamin status in patients on chronic anticonvulsant therapy. Int J Vitam Nutr Res. 1982;52(4):375-385.
84. Rogers SA. Depression Cured At Last. Syracuse, NY: Prestige Publishing; 1997.
85. Tada K, Yokoyama Y, Nakagawa H, Arakawa T. Vitamin B6 dependent xanthurenic aciduria (the second report). Tohoku J Exp Med. 1968;95(2):107-114.
86. Bender DA, Laing AE, Vale JA, Papadaki L, Pugh M. The effects of oestrogen administration on tryptophan metabolism in rats and in menopausal women receiving hormone replacement therapy. Biochem Pharmacol. 1983;32(5):843-848.
87. Infante JP, Huszagh VA. Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett. 2000;468(1):1-5.
88. Trauner DA, Horvath E, Davis LE. Inhibition of fatty acid beta oxidation by influenza B virus and salicylic acid in mice: implications for Reye's syndrome. Neurology. 1988;38(2):239-241.
89. Rogers SA. Lipoic acid as a potential first agent for protection from mycotoxins and treatment of mycotoxicosis. Arch Environ Health. 2003;58(8):528-532.
90. Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo- controlled pilot trial. Free Radic Biol Med. 1999;27(3-4):309-314.
91. Borcea V, Nourooz-Zadeh J, Wolff SP, et al. alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria [In Process Citation]. Free Radic Biol Med. 1999;26(11-12):1495- 1500.
92. Burkart V, Koike T, Brenner HH, Imai Y, Kolb H. Dihydrolipoic acid protects pancreatic islet cells from inflammatory attack. Agents Actions. 1993;38(1-2):60-65.
93. Packer L, Kraenter K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001;17(10):888-895.
94. Konrad T, Vicini P, Kusterer K, et al. alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care. 1999;22(2):280-287.
95. Lee YJ, Kang IJ, Bunger R, Kang YH. Mechanisms of pyruvate inhibition of oxidant-induced apoptosis in human endothelial cells. Microvasc Res. 2003;66(2):91-101.
96. Lykkesfeldt J, Hagen TM, Vinarsky V, Ames BN. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes-reversal with (R)-alpha-lipoic acid supplementation. FASEB J. 1998;12(12):1183-1189.
97. Yang CS, Chen WY, Tsai PJ, Kuo JS. Alpha-tocopherol acetate significantly suppressed the increase in heart interstitial 8-hydroxydeoxyguanosine following myocardial ischemia and reperfusion in anesthetized rats. Clin Chim Acta. 1999;285(1-2):163-168.
98. Matsui M, Nishigori C, Toyokuni S, et al. The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2'-deoxyguanosine in arsenic-related Bowen's disease. J Invest Dermatol. 1999;113(1):26-31.
99. Bralley JA, Lord RS. Laboratory Evaluations in Molecular Medicine: Nutrients, Toxicants and Cell Controls. Norcross, GA: IAMM; 2000.
100. Rybak LP, Husain K, Whitworth C, Somani SM. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol Sci. 1999;47(2):195-202.
101. Suh JH, Shigeno ET, Morrow JD, et al. Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-(alpha)-lipoic acid. FASEB J. 2001;15(3):700-706.
102. Hagen, T.M., Increased mitochondrial decay and oxidative stress in the aging rat heart: improvement by dietary supplementation with (R)-a-lipoic acid. Free Rad Chem Biol Med. 2000;27:262-271.
103. Hagen TM, et al. Mitochondrial decay in the aging rat heart: evidence for improvement by dietary supplementation with acetyl-L-carnitine and/or lipoic acid. Ann NY Acad Sci. 2002;959:491-507.
104. Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci USA. 200;99(4):1876-1881.
105. Markaverich BM, Gregory RR, Alejandro M, et al. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res. 1990;50(5):1470-1478.
106. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA. 1990;87(22):8931-8934.
107. Mortensen SA, Vadhanavikit S, Muratsu K, Folkers K. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12(3):155-162.
108. Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci. 1998;156(1)41-46.
109. Kawaguchi A, Bloch K. Inhibition of glutamate dehydrogenase and malate dehydrogenases by palmitoyl coenzyme A. J Biol Chem. 1976;251(5):1406-1412.
110. Dissmann R, Linderer T, Schroder R. Estimation of enzymatic infarct size: direct comparison of the marker enzymes creatine kinase and alpha-hydroxybutyrate dehydrogenase. Am Heart J. 1998;135(1):1-9.
111. Azuma J, Hasegawa H, Sawamura A, Awata N, Harada H, Ogura K, Kishimoto S, et al. Taurine for treatment of congestive heart failure. Int J Cardiol. 1982;2(2):303-304.
112. Huxtable R. Taurine in Nutrition and Neurology. New York, NY: Plenum; 1982
113. Hayes KC, Pronczuk A, Addesa AE, Stephan ZF. Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr. 1989;49(6):1211-1216.
114. Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37(1):1-18.
115. Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact. 1989;70(1-2):89-101.
116. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol. 1997;8(6):569-573.
117. Triebig G, Schaller KH, Weltle D. Neurotoxicity of solvent mixtures in spray painters. I. Study design, workplace exposure, and questionnaire. Int Arch Occup Environ Health. 1992;64(5):353-359.
118. Rose ML, Madren J, Bunzendahl H, Thurman RG. Dietary glycine inhibits the growth of B16 melanoma tumors in mice. Carcinogenesis. 1999;20(5):793-798.
119. File SE, Fluck E, Fernandes C. Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults. J Clin Psychopharmacol. 1999;19(6):506-512.
120. Schwartz BL, Hashtroudi S, Herting RL, Handerson H, Deutsch SI. Glycine prodrug facilitates memory retrieval in humans. Neurology. 1991;41(9):1341-1343.
121. Minami M, Ando T, Hashikawa SN, et al. Effect of glycine on Helicobacter pylori in vitro. Antimicrob Agents Chemother. 2004;48(10):3782-3788.
122. Rose ML, Cattley RC, Dunn C, Wong V, Li X, Thurman RG. Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14,643. Carcinogenesis. 1999;20(11):2075-2081.
123. Luckenhach T, Epel D. Nitromusk and polycyclic musk compounds as long-term inhibitors of cellular xenobiotic defense systems mediated by multidrug transporters. Environ Health Perfect. 2005;113(1):17-24.
124. Darbre PD, Aljarrah A, Miller WR, Coldham NG, Sauer MJ, Pope GS. Concentrations of parabens in human breast tumours. J Appl Toxicol. 2004;24(1):5-13.
125. Elder RL. Final report on the safety assessment of methylparaben, ethylparaben, propylparaben and butylparaben. J Am Coll Toxicol. 1984;3:5-13.
126. Soni MG, Burdock GA, Taylor SL, Greenberg NA. Safety assessment of propyl paraben: a review of the published literature. Food Chem Toxicol. 2001;39(6):513-532.
127. Whelan J. Are deodorants safe? New Scientist. 2004;181(2431):11.
128. Dark DS, Pingleton SK. Nutrition and nutritional support in critically ill patients. J Intensive Care Med. 1993;8:16.
129. Giner M, Laviano A, Meguid MM, Gleason JR. In 1995 a correlation between malnutrition and poor outcome in critically ill patients still exists. Nutrition. 1996;12(1):23-29.
130. Nathans AB, Neff MJ, Jurkovich GJ, et al. Randomized, prospective trial of anti-oxidant supplementation in critically ill surgical patients. Ann Surg. 2002;236:814-822.
131. Porter JM, Ivatury RR, Azimuddin K, et al. Antioxidant therapy in complications after trauma: early results of a prospective randomized study. Ann Surg. 1999;65:478-483.
132. Roberts MM, Lord RS. ION Handbook. Norcross, GA: Metametrix Clinical Laboratory; 2005.